SKIN The Journal of Cutaneous Medicine

Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study

Jennifer Soung, Lisa Tiu, Karen Veverka, Chih-Ho Hong

Page s26

Poster PDF

Phase 3 Trial Demonstrates that MC2-01 Cream has Improved Treatment Efficacy Compared to Calcipotriene Plus Betamethasone Dipropionate Topical Suspension in Patients with Mild to Moderate Psoriasis Vulgaris

Johan Selmer, Birgitte Vestbjerg, Morten Pr?stegaard, Linda Stein Gold

Page s36

Poster PDF

Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam: Results from a Phase III Randomized Controlled Trial

Mark Lebwohl, Jean-Philippe Lacour, Monika Liljedahl, Charles Lynde, Marie H M?rch, Diamant Tha?i, Richard B Warren

Page s32

Poster PDF

Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial

Mark Lebwohl, Jean-Philippe Lacour, Monika Liljedahl, Charles Lynde, Marie H M?rch, Diamant Tha?i, Richard B Warren

Page s31

Poster PDF

Real World Experience with Calicpotriene and Betamethasone Dipropionate Foam 0.005%/0.064% (Cal/BD Foam) in the Treatment of Adult Psoriasis Itch from Retrospective Chart Review

Jashin Wu, Karen Veverka, Minyi Lu, April W Armstrong

Page S15

Poster PDF

Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam as a Treatment for Nail Psoriasis

Shifa Akhtar, Mariana Perez, Jessica Sharma, Agnese Canazza, Martin Zaiac

Page 556-559

PDF

Phase 3 Trial Demonstrating High Efficacy, Favourable Safety, and Convenience of a Novel Calcipotriene and Betamethasone Dipropionate Cream

Linda Stein Gold, Andreas Pinter, April Armstrong, Lars Iversen, Morten Praestegaard, Matthias Augustin

Page s128

Poster PDF

Enhanced Skin Deposition of Betamethasone Dipropionate into the Skin of Human Volunteers from Calcipotriene/Betamethasone Dipropionate Cream Compared to Topical Suspension

Zoe D Draelos, Matthew M Draelos, Morten Praestegaard

Page s54

Poster PDF

Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Cream for the Treatment of Plaque Psoriasis Evaluated from Pooled Phase 3 Data

Linda Stein Gold, Andreas Pinter, Matthias Augustin

Page s204

Poster PDF

Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) Cream Demonstrates High Efficacy and Convenience in Skin of Color Patients with Plaque Psoriasis

Valerie Callender, Susan Taylor, Fran Cook-Bolden

Page s55

Poster PDF

Patient Preferences for Vehicle and Overall Preference of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam and Gel in the PSO-INSIGHTFUL Study

Chih-Ho Hong, Dharm S Patel, Katja W Lophaven

Page S11

Poster PDF

Patient Perspectives on use of a water-based Calcipotriene and Betamethasone Dipropionate Cream for the treatment of Plaque Psoriasis

Michael Vecchiolla, Neal Bhatia

Page s127

Poster PDF

Calcipotriene and betamethasone dipropionate cream demonstrates superior efficacy in moderate plaque psoriasis compared to topical suspension: a subgroup analysis of a phase 3 trial

Linda Stein Gold, John Selmer, Morten Præstegaard, April Armstrong

Page s10

Poster PDF

Calcipotriene And Betamethasone Dipropionate Cream Demonstrates High Treatment Success In Patients With Scalp Psoriasis

Andreas Pinter, Morten Præstegaard, Johan Selmer, Adam Reich

Page s9

Poster PDF

Treatment Success in Mild Psoriasis Patients With Fixed-Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam: Results From the PSO-FAST Trial

Karen Veverka, Jes Hansen, Maria Yaloumis, Leon Kircik, Linda Stein Gold

Page s76

Poster PDF

Search

Search Results